That this House notes the comments made by the hon Member for South Thanet on the National Institute for Clinical Excellence's (NICE) draft guidance on drugs for Alzheimer's; welcomes the Minister's statement that NICE should consider the wider implications of not approving Alzheimer's drugs' use, especial ly the benefits and costs to carers as well as patients; calls on NICE to reconsider the proposals to discontinue the prescription of Alzheimer's drugs on the NHS; and urges Ministers to listen closely to the concerns of honourable Members and their constituents on the Alzheimer's Society lobby of Parliament on 16th March.

That this House notes the comments made by the hon Member for South Thanet on the National Institute for Clinical Excellence's (NICE) draft guidance on drugs for Alzheimer's; welcomes the Minister's statement that NICE should consider the wider implications of not approving Alzheimer's drugs' use, especial ly the benefits and...

That this House believes that consumers have a right to expect full and impartial information about the potential risks and side effects of prescription medication; further believes that this requires a robust regulatory framework to ensure that information is not only publicly available but also acted upon promptly; and in light of continuing consumer disquiet about Seroxat and similar concerns about other medicines, calls for an urgent, full, independent and open review of the UK drug regulatory system.

That this House believes that consumers have a right to expect full and impartial information about the potential risks and side effects of prescription medication; further believes that this requires a robust regulatory framework to ensure that information is not only publicly available but also acted upon promptly; and in...

That this House expresses concern at the tragic deaths associated with the anti-depressant drug Seroxat and the news that GlaxoSmithKline suppressed news of two 1998 studies that demonstrated that the drug was no more effective than placebos; notes with alarm the Department of Health's view that Seroxat can make the symptoms of depression more severe and the decision of a court that Seroxat was responsible for a change in the behaviour of a man who took his own life and that of his family; and calls for a full investigation of the conduct of GlaxoSmithKline who appear to have put their private greed before public safety.

That this House expresses concern at the tragic deaths associated with the anti-depressant drug Seroxat and the news that GlaxoSmithKline suppressed news of two 1998 studies that demonstrated that the drug was no more effective than placebos; notes with alarm the Department of Health's view that Seroxat can make the...

That this House welcomes the introduction, a year ago, of the National Health Service risk sharing scheme which provided for people with multiple sclerosis to receive treatment with beta interferons and glatiramer acetate while data on long-term effectiveness is gathered; shares the frustration of thousands of people with MS who could benefit from this treatment and who have not had access to these drugs a full year after the scheme was introduced; and believes that the Government should take steps to ensure all those meeting the criteria for treatment under guidelines set by the Association of British Neurologists are assessed and receiving treatment by the Department of Health's target date of November 2003.

That this House welcomes the introduction, a year ago, of the National Health Service risk sharing scheme which provided for people with multiple sclerosis to receive treatment with beta interferons and glatiramer acetate while data on long-term effectiveness is gathered; shares the frustration of thousands of people with MS who...

That this House notes that community pharmacists offer their local communities convenient access to NHS services; recognises their role in reducing the burden on local general practitioners; notes the recommendations of the Office of Fair Trading that pharmaceutical dispensing should be made open to free market competition; is concerned that supermarkets would use their market power to undermine and eliminate small local pharmacies and thereby effect a net loss of NHS provision; and urges Her Majesty's Government not to accept this recommendation of the OFT.

That this House notes that community pharmacists offer their local communities convenient access to NHS services; recognises their role in reducing the burden on local general practitioners; notes the recommendations of the Office of Fair Trading that pharmaceutical dispensing should be made open to free market competition; is concerned that...

That this House welcomes the National Institute for Clinical Excellence's Technology Appraisal Guidance No. 43 on the use of newer, atypical antipsychotic drugs for the treatment of schizophrenia, issued in June 2002; believes that the guidance is a real step forward in delivering better care for those with schizophrenia; recognises the importance of ensuring that patients have an informed choice about their treatment options; recalls the NHS' statutory obligation to ensure that all NICE recommendations are implemented within three months of issue; notes the concerns raised at the Rethink severe mental illness conference, Only the Best in December 2002 over the slowness of implementation; and urges NHS trusts, health authorities and primary care trusts to ensure that sufficient funding is made available to implement the NICE guidance quickly and effectively to improve the lives of those with schizophrenia.

That this House welcomes the National Institute for Clinical Excellence's Technology Appraisal Guidance No. 43 on the use of newer, atypical antipsychotic drugs for the treatment of schizophrenia, issued in June 2002; believes that the guidance is a real step forward in delivering better care for those with schizophrenia; recognises...

That this House is deeply concerned about the effects of the anti-depressant drug Seroxat; notes that the World Health Organisation puts the drug at the top of its league table of drugs that have difficulties of withdrawal and that over 1,000 Seroxat users in the United Kingdom are taking legal action against the manufacturer, Glaxo SmithKline, after funding that the drug can lead to dependency and result in severe withdrawal symptoms including muscle spasms, insomnia, anxiety and depression and, in some cases, aggression and violence; is further concerned that the labelling of the drug does not mention the difficulties of withdrawal and that such symptoms are often misdiagnosed by doctors as a relapse into depression; further notes that the manufacturer has already been forced to drop adverts for the drug in the United States of America after a court rules that they could be misleading; and calls upon the Department of Health to look into the labelling and availability of the drug.

That this House is deeply concerned about the effects of the anti-depressant drug Seroxat; notes that the World Health Organisation puts the drug at the top of its league table of drugs that have difficulties of withdrawal and that over 1,000 Seroxat users in the United Kingdom are taking legal...

That this House notes that arthritis affects one in five of the population and is the single biggest cause of physical disability in the UK; is concerned that postcode prescribing persists in relation to new treatments recently recommended by NICE; and calls on the Government to make arthritis a health priority.

That this House notes that arthritis affects one in five of the population and is the single biggest cause of physical disability in the UK; is concerned that postcode prescribing persists in relation to new treatments recently recommended by NICE; and calls on the Government to make arthritis a health...

That this House congratulates the 'Beat the Benzos' campaign in highlighting the over-prescription of tranquilliser drugs known as benzodiazepines, including Ativan, Temazepam and Valium; supports their objective in bringing about the full implementation of prescription guidelines by general practitioners; calls on the Government to provide greater support services for involuntary and voluntary addicts of these drugs to integrate anti-benzodiazepine measures in anti-drug policies and to review disability benefit guidelines to ensure recognition of benzodiazepine addiction; and notes with great interest the recent court victory by Mr Ray Nimmo in which he successfully won compenstion for the past over-prescription of Valium by his then general practitioner.

That this House congratulates the 'Beat the Benzos' campaign in highlighting the over-prescription of tranquilliser drugs known as benzodiazepines, including Ativan, Temazepam and Valium; supports their objective in bringing about the full implementation of prescription guidelines by general practitioners; calls on the Government to provide greater support services for involuntary...

That this House believes people with cystic fibrosis should not have to pay prescription charges.

That this House believes people with cystic fibrosis should not have to pay prescription charges.